Skip to main content
Barry Ladizinski on Muck Rack

Barry Ladizinski

As seen in: JAMA (The Journal of the American Medical Association), The New England Journal of Medicine, The Journal of Allergy & Clinical Immunology, Journal of The American Academy of Dermatology (JAAD)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry

Contact Barry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis

|
By Amy S. Paller, Barry Ladizinski, Pedro Mendes-Bastos, Elaine Siegfried
| JAMA (The Journal of the American Medical Association) Verified
Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis Upadacitinib Treatment in Adolescents With Atopic Dermatitis Amy S. Paller, MD, MS; Barry Ladizinski, MD, MPH, MBA; Pedro Mendes-Bastos, MD; Elaine Siegfried, MD; Weily Soong, MD; Vimal H. Prajapati, MD; Peter Lio, MD; Jacob P. Thyssen, MD, PhD, DmSci; Eric L. Simpson, MD, MCR; Andrew M. Platt, PhD; Eliza M. Raymundo, MD; Jianzhong Liu, MD, MS; Brian M.
Open in Who Shared View Duplicates (2) Issue with article?

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials | Adolescent Medicine | JAMA Dermatology | JAMA Network

|
By Amy S. Paller, Barry Ladizinski, Pedro Mendes-Bastos, Elaine Siegfried
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question Does upadacitinib safely improve moderate-to-severe atopic dermatitis in adolescents? Findings Among 552 adolescents participating in 3 randomized clinical trials, upadacitinib administered once daily was generally well tolerated through 16 weeks.
Open in Who Shared Issue with article?

Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials

|
By Pedro Mendes-Bastos, Barry Ladizinski, Emma Guttman-Yassky, Ping Jiang
| Journal of The American Academy of Dermatology (JAAD) Verified
Background Acne is the most frequent adverse event associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis. Objective To characterize the adverse event of acne associated with upadacitinib. Methods This was a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials of upadacitinib, alone (NCT03569293 and NCT03607422) or in combination with topical corticosteroids (NCT03568318).
Open in Who Shared Issue with article?
See all 4 articles